GSK2033

SKU: orb1308253

Description

GSK2033

Research Area

Metabolism Research

Key Properties

• CAS Number: 1221277-90-2
• MW: 591.66
• Purity: 99.70%
• Formula: C₂₉H₂₈F₃NO₅S₂
• SMILES: Cc1cc(C)c(c(C)c1)S(=O)(=O)N(Cc1ccc(o1)C(F)(F)F)Cc1ccc(cc1)-c1cccc(c1)S(C)(=O)=O
• Target: Liver X Receptor
• Solubility: DMSO:11.9 mg/mL (20.11 mM)

Bioactivity

• Target IC50:
  LXRα:7 (pic50)|LXRβ:7.4(pic50)
• In Vivo:
  GSK2033 (one month) treatment, does not have obviously effects on hepatic triglyceride levels. GSK2033 treatment also have no effects on plasma triglyceride levels.
• In Vitro:
  GSK2033 dose-dependently inhibits basal transcription in full-length LXRα or full-length LXRβ cotransfection assays (IC50s: 17 nM and 9 nM, respectively). GSK2033 also effectively inhibits the transcription of an ABCA1 driven luciferase reporter dose-dependently (IC50s: 52 nM for LXRα and 10 nM for LXRβ). GSK2033 also suppresses the expression of both of fatty acid synthase (FASN) and SREBP1.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, Liver X Receptor, Liver X receptor, LiverXReceptor, LXR, LXRα, LXRβ, Inhibitor, GSK2033, GSK-2033, GSK 2033

Compound Identifiers

PubChem CID

46203250